Marco Rossi

List of Publications by Year
in descending order

94 papers	4,163 citations	126708 33 h-index	110170 64 g-index
95 all docs	95 docs citations	95 times ranked	5797 citing authors

#	Article	IF	Citations
1	Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 2005, 437, 147-153.	13.7	513
2	Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity. Journal of Immunology, 2005, 175, 1373-1381.	0.4	286
3	Indoleamine 2,3-dioxygenaseâ€“expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 2009, 114, 555-563.	0.6	235
4	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	3.2	213
5	Targeting miR-21 Inhibits <i>In Vitro</i> and <i>In Vivo</i> Multiple Myeloma Cell Growth. Clinical Cancer Research, 2013, 19, 2096-2106.	3.2	195
6	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia, 2018, 32, 1948-1957.	3.3	179
7	miRâ€29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myelomaâ€related bone disease. Journal of Cellular Physiology, 2013, 228, 1506-1515.	2.0	156
8	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death and Disease, 2012, 3, e436-e436.	2.7	137
9	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012, 120, 5002-5013.	0.6	121
10	miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget, 2015, 6, 12837-12861.	0.8	112
11	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer, 2013, 49, 593-603.	1.3	106
12	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia, 2015, 29, 2173-2183.	3.3	104
13	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle, 2013, 12, 3650-3662.	1.3	96
14	A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 2011, 25, 707-711.	3.3	93
15	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget, 2015, 6, 27343-27358.	0.8	89
16	Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 838-846.	0.8	84
17	In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells. PLoS ONE, 2014, 9, e89659.	1.1	77
18	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 2020, 136, 199-209.	0.6	76

#	Article	IF	Citations
19	A peroxisome proliferatorâ€activated receptor gamma (<i>PPARG</i>) polymorphism is associated with zoledronic acidâ€related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. British Journal of Haematology, 2011, 154, 529-533.	1.2	69
20	Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation<i>In Vitro</i>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells<i>In Vivo</i>. Clinical Cancer Research, 2011, 17, 1984-1997.	3.2	67
21	<i>In vivo</i> antiâ€myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. British Journal of Haematology, 2008, 143, 520-531.	1.2	59
22	Molecular Targets for the Treatment of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 757-767.	0.8	59
23	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Advances, 2017, 1, 455-466.	2.5	54
24	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood, 2018, 132, 1050-1063.	0.6	52
25	MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia, 2018, 32, 1003-1015.	3.3	51
26	Dendritic cells have the option to express IDO-mediated suppression or not. Blood, 2005, 105, 2618-2618.	0.6	47
27	Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. Cancers, 2019, 11, 990.	1.7	47
28	MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches. Current Pharmaceutical Biotechnology, 2014, 15, 459-467.	0.9	46
29	Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 1099-1108.	1.5	45
30	From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario. Current Drug Targets, 2013, 14, 1144-1149.	1.0	45
31	Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S83-S93.	1.4	39
32	miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia, 2019, 33, 487-498.	3.3	39
33	A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer Journal, 2016, 6, e511-e511.	2.8	37
34	Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget, 2018, 9, 20119-20133.	0.8	35
35	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 2019, 11, 236.	1.7	35
36	Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study. Radiologia Medica, 2013, 118, 930-948.	4.7	33

#	Article	IF	Citations
37	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. Haematologica, 2020, 106, 185-195.	1.7	33
38	miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia, 2021, 35, 823-834.	3.3	33
39	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684638.	1.6	33
40	Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?. European Journal of Cancer, 2006, 42, 1530-1538.	1.3	29
41	Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. Journal of Hematology and Oncology, 2019, 12, 32.	6.9	28
42	Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. The Hematology Journal, 2003, 4, 346-350.	2.0	26
43	Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?. Human Immunology, 2002, 63, 1194-1200.	1.2	25
44	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers, 2020, 12, 320.	1.7	24
45	Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. Leukemia, 2016, 30, 2419-2422.	3.3	22
46	Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy. Current Cancer Drug Targets, 2009, 9, 854-870.	0.8	20
47	Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling. ACS Omega, 2020, 5, 30436-30443.	1.6	20
48	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	2.5	19
49	MicroRNAs in multiple myeloma and related bone disease. Annals of Translational Medicine, 2015, 3, 334.	0.7	19
50	A Comprehensive Safety Evaluation of Trabectedin and Drugâ€"Drug Interactions of Trabectedin-Based Combinations. BioDrugs, 2014, 28, 499-511.	2.2	13
51	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Review of Hematology, 2019, 12, 665-684.	1.0	13
52	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
53	Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. Non-coding RNA, 2020, 6, 37.	1.3	10
54	Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor. Blood, 2013, 122, 124-124.	0.6	10

#	Article	IF	Citations
55	A Novel Bispecific T-Cell Engager (CD1a x CD3Îµ) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells. Cancers, 2022, 14, 2886.	1.7	9
56	Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in Oncology, 2021, 11, 624405.	1.3	7
57	Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 1394-1396.	0.6	5
58	Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. Diagnostic Microbiology and Infectious Disease, 2018, 92, 230-234.	0.8	5
59	A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. Annals of Hematology, 2020, 99, 331-341.	0.8	4
60	Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	1.1	3
61	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. Blood, 2019, 134, 4355-4355.	0.6	2
62	Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability. Blood, 2014, 124, 3417-3417.	0.6	2
63	FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e94.	0.2	1
64	Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety. Blood, 2018, 132, 5869-5869.	0.6	1
65	Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells. Blood, 2013, 122, 4451-4451.	0.6	1
66	MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile.. Blood, 2012, 120, 2941-2941.	0.6	1
67	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood, 2018, 132, 1418-1418.	0.6	1
68	Mycosis fungoides and gastric Tâ€'cell lymphoma: A case report. Molecular and Clinical Oncology, 2020, 13, 15.	0.4	1
69	Enlarging the clinical spectrum of chorea-acanthocytosis. Neurological Sciences, 2021, 43, 1453.	0.9	1
70	Multiple myeloma-related bone disease: state-of-art and next future treatments. International Journal of Hematologic Oncology, 2015, 4, 33-47.	0.7	0
71	Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. Transfusion and Apheresis Science, 2020, 59, 102911.	0.5	0
72	Role of NPM in the Control of Genetic Stability and Tumorigenesis.. Blood, 2005, 106, 1595-1595.	0.6	0

#	Article	IF	Citations
73	Mature Conventional Human Dendritic Cells Express Indoleamine 2,3-Dioxygenase and Support the Relative Expansion of Autologous Regulatory T Cells.. Blood, 2007, 110, 1804-1804.	0.6	0
74	Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacytylase Inhibitor.. Blood, 2007, 110, 4790-4790.	0.6	0
75	Regulatory T Cells Expanded by Autologous Mature Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase Are Potent Suppressors of T Cell Proliferation.. Blood, 2008, 112, 1553-1553.	0.6	0
76	SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. Blood, 2010, 116, 452-452.	0.6	0
77	MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence. Blood, 2011, 118, 2910-2910.	0.6	0
78	Emerging Role of MicroRNAs in the Pathophysiology of Immune System. , 0, , .		0
79	Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease. Blood, 2012, 120, 3960-3960.	0.6	0
80	Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease. Blood, 2013, 122, 683-683.	0.6	0
81	Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo. Blood, 2013, 122, 4489-4489.	0.6	0
82	MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma. Blood, 2014, 124, 2060-2060.	0.6	0
83	Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines. Blood, 2015, 126, 3019-3019.	0.6	0
84	Abstract 1077: Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential. , 2016, , .		0
85	Multiple Myeloma in Patients with HCV-Related Disease:a Case Report. Blood, 2016, 128, 5700-5700.	0.6	0
86	Abstract 2550: Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity. , 2017, , .		0
87	Abstract 4431: Phosphoproteomic analysis of miR-21 modulation in Th17 cells: Potential implications for multiple myeloma bone disease therapy. , 2018, , .		0
88	Abstract 2827: Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma. , 2018, , .		0
89	Abstract 1783: UMG1, a novel humanized monoclonal antibody against a glysosylated-CD43-related epitope, induces antibody-dependent cellular cytotoxicity (ADCC) on human T-cell acute lymphoblastic leukemia cells. , 2018, , .		0
90	Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation. Blood, 2018, 132, 2449-2449.	0.6	0

#	Article	IF	Citations
91	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃƒÂ¶m Macroglobulinemia. Blood, 2018, 132, 1585-1585.	0.6	0
92	PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 3107-3107.	0.6	0
93	Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM. Blood, 2019, 134, 505-505.	0.6	0
94	A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells. Blood, 2019, 134, 4411-4411.	0.6	0